Deals
Arena Pharma CEO Targets Brain Diseases as Next Drug Frontier
Source: Nomadsoul1/iStockphoto via Getty Images
This article is for subscribers only.
Arena Pharmaceuticals Inc. shares have nearly tripled since Chief Executive Amit Munshi took the helm in 2016 and now he’s setting a new course as the company makes its foray into drug development for brain diseases.
A new subsidiary called Arena Neuroscience Inc. may focus on movement disorders like Parkinson’s and Lou Gehrig’s diseases, Munshi said in an interview. Arena also recently expanded a relationship with Beacon Discovery, the 2016 spinoff of Arena’s drug discovery pipeline, and plans to reveal autoimmune disease targets later this year.